University of Pennsylvania Doses First Patient In Phase IIa Clinical...

University of Pennsylvania Doses First Patient In Phase IIa Clinical Trial Using CardioCell 's Stem Cell Therapy To Treat Chronic Heart Failure Due To Non-Ischemic Cardiomyopathy The Only Chronic HF Clinical Trial Using Ischemia-Tolerant Mesenchymal Stem Cells Continues Recruitment at Emory University, Northwestern University and the University of Pennsylvania PHILADELPHIA-- --CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that creates allogeneic stem-cell therapies for cardiovascular indications, announces the treatment of its first patient in the University of Pennsylvania's Phase IIa clinical trial for chronic heart failure of non-ischemic cardiomyopathy.

http://ift.tt/1xZtdwl